MedTrace Logo

DHFR 19 bp Deletion Polymorphism and Folic Acid Utilization

NCT03319979 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 117

Last updated 2017-10-24

No results posted yet for this study

Summary

A genetic variation in the gene for the protein dihydrofolate reductase (DHFR) that is necessary to utilize folic acid (a synthetic form of the B vitamin folate found in supplements and fortified food), increases the risk for breast cancer in multivitamin users and, when present in mothers who used folic acid supplements during pregnancy, increases the risk for cancer of the eye of their children. The aim of the proposed research is to understand how a common genetic variation in the gene for DHFR affects the function of this protein and the ability of the body to use folic acid.

Conditions

  • Characterize rs70991108 Polymorphism of DHFR Gene

Sponsors & Collaborators

  • Tufts University

    lead OTHER

Principal Investigators

  • Ligi Paul, Ph.D. · Tufts University

Eligibility

Min Age
21 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2015-03-31
Completion
2015-03-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03319979 on ClinicalTrials.gov